Long-Term Outcomes of BRAF-MEK Inhibitor Combinations

, , ,

Peer Exchange | <b>Latest Advances in ALK-Positive and BRAF-Positive V600E NSCLC: Efficacy Updates, Brain Metastases Management, and Optimal Treatment Sequencing </b>

Panelists discuss recent data on progression-free survival (PFS) and duration of response (DOR) for BRAF-MEK inhibitor combinations, including encorafenib + binimetinib and dabrafenib + trametinib, while also addressing emerging safety signals, differences in response based on treatment lines, and considerations for dose modifications and sequencing strategies in clinical practice.

  1. All: Please discuss the recent data on PFS and DOR for BRAF-MEK inhibitors combinations.
    1. Encorafenib + binimetinib (Riely GJ, et al. J Clin Oncol. 2023)
    2. Dabrafenib + trametinib (Planchard D, et al. J Thorac Oncol. 2022)
  2. Have any new safety signals emerged from long-term follow-up?
    1. Encorafenib + binimetinib (Smit E, et al. 2024.WCLC. MA06.13
    2. Encorafenib + binimetinib (Riely G, et al. 2024.ESMO.LBA56)
      1. Impression of overall survival data
      2. Impact on clinical practice
      3. Difference in responses in first line vs second line
  3. How do you choose between different BRAF-MEK inhibitor
  4. Based on the recent data presented at ESMO, how do you approach dose modifications?
  5. First-line immunotherapy vs BRAF and MEK inhibitors (Di Federico A, et al. 2024. ESMO. Abstract 1299p)
  6. Treatment sequences in BRAF-V600 mutant (Wiesweg M, et al. 2024. ESMO Abstract 1300p

Related Content:

Future Directions in ALK-Positive and BRAF-Positive NSCLC Management
Precision BRAF Therapy: Optimizing Dosing, Sequencing, and Toxicity Management in NSCLC
Combination Therapies in BRAF-Positive NSCLC